| DB01254 | Dasatinib | For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. |
| DB01259 | Lapatinib | Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma. |
| DB00908 | Quinidine | For the treatment of ventricular pre-excitation and cardiac dysrhythmias |
| DB06589 | Pazopanib | Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) |
| DB00818 | Propofol | Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. |
| DB08820 | Ivacaftor | When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [L768, FDA Label].
When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. |
| DB01764 | Dalfopristin | For the treatment of bacterial infections (usually in combination with quinupristin). |
| DB01369 | Quinupristin | For the treatment of bacterial infections (usually in combination with dalfopristin). |
| DB08827 | Lomitapide | Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C). |
| DB09073 | Palbociclib | Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. |
| DB06717 | Fosaprepitant | For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. |
| DB09238 | Manidipine | For the treatment of hypertension. |
| DB11767 | Sarilumab | Indicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate. |
| DB13941 | Piperaquine | For the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB11638]. |
| DB12332 | Rucaparib | Indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. |
| DB00501 | Cimetidine | For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion. |
| DB00921 | Buprenorphine | For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence. |
| DB01173 | Orphenadrine | Indicated for the treatment of Parkinson's disease. |
| DB00188 | Bortezomib | For treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
| DB00289 | Atomoxetine | For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures. |